Kestra Medical Technologies (NASDAQ:KMTS) Insider Traci Umberger Sells 30,000 Shares of Company Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Traci Umberger sold 30,000 shares of the company’s stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $30.03, for a total transaction of $900,900.00. Following the completion of the transaction, the insider owned 195,825 shares of the company’s stock, valued at $5,880,624.75. This trade represents a 13.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Kestra Medical Technologies Price Performance

KMTS opened at $30.61 on Friday. Kestra Medical Technologies, Ltd. has a twelve month low of $17.34 and a twelve month high of $31.04. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.33. The company has a fifty day simple moving average of $26.64 and a 200 day simple moving average of $23.79.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings data on Monday, September 14th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). The firm had revenue of $30.97 million during the quarter. Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. As a group, sell-side analysts expect that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Evercore began coverage on Kestra Medical Technologies in a research report on Tuesday, October 20th. They set an “outperform” rating and a $34.00 target price on the stock. Oppenheimer began coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating for the company. Wolfe Research set a $30.00 price objective on Kestra Medical Technologies in a research note on Wednesday, July 15th. JPMorgan Chase & Co. initiated coverage on Kestra Medical Technologies in a research note on Monday, August 10th. They set an “overweight” rating and a $30.00 price objective for the company. Finally, Wall Street Zen downgraded Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, September 12th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $29.00.

Institutional Trading of Kestra Medical Technologies

Institutional investors have recently added to or reduced their stakes in the stock. Corient Private Wealth LP raised its holdings in Kestra Medical Technologies by 284.2% in the second quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock valued at $1,542,000 after acquiring an additional 44,839 shares in the last quarter. Sei Investments Co. boosted its stake in Kestra Medical Technologies by 22.6% during the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock valued at $4,726,000 after acquiring an additional 43,753 shares during the last quarter. Spartan Wealth Advisory Services LLC acquired a new position in Kestra Medical Technologies during the 1st quarter worth $603,000. Quantinno Capital Management LP acquired a new position in Kestra Medical Technologies during the 1st quarter worth $431,000. Finally, Bank of New York Mellon Corp increased its position in shares of Kestra Medical Technologies by 47.2% in the 1st quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock worth $1,397,000 after purchasing an additional 22,471 shares during the last quarter.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.

The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.